Immunome (NASDAQ:IMNM) Stock Gets Price Target Cut from Piper Sandler

Immunome (NASDAQ:IMNM) had its target price trimmed by Piper Sandler from $33.00 to $30.00 in a report published on Tuesday morning, MarketBeat.com reports. The firm currently has an overweight rating on the stock.

A number of other brokerages have also issued reports on IMNM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Thursday, October 15th. Wall Street Zen cut Immunome from a “sell” rating to a “strong sell” rating in a research note on Sunday, October 4th. Alliance Global Partners initiated coverage on Immunome in a report on Monday, September 21st. They set a “buy” rating and a $32.00 price objective on the stock. Stifel Nicolaus began coverage on Immunome in a research report on Wednesday, September 30th. They set a “hold” rating and a $24.00 target price for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $35.00 target price on shares of Immunome in a research report on Tuesday, October 27th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunome presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.85.

Immunome Price Performance

Shares of IMNM opened at $18.70 on Tuesday. Immunome has a 1-year low of $16.11 and a 1-year high of $30.06. The company has a 50-day moving average of $20.82 and a 200 day moving average of $22.27. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -7.08 and a beta of 2.68.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.14). On average, equities analysts anticipate that Immunome will post -2.59 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Jack Higgins sold 13,200 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the transaction, the insider directly owned 65,050 shares in the company, valued at approximately $1,647,066. This trade represents a 16.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 7.21% of the company’s stock.

Institutional Trading of Immunome

A number of hedge funds have recently bought and sold shares of the stock. Edgestream Partners L.P. purchased a new stake in shares of Immunome during the 3rd quarter worth $2,923,000. Russell Investments Group Ltd. lifted its position in shares of Immunome by 213.6% during the third quarter. Russell Investments Group Ltd. now owns 93,946 shares of the company’s stock valued at $2,021,000 after buying an additional 63,985 shares during the last quarter. Three Bridge Wealth Advisors LLC purchased a new stake in shares of Immunome during the third quarter valued at about $164,000. Alps Advisors Inc. boosted its holdings in shares of Immunome by 31.5% in the 3rd quarter. Alps Advisors Inc. now owns 150,502 shares of the company’s stock valued at $3,237,000 after buying an additional 36,062 shares in the last quarter. Finally, Sterling Capital Management LLC boosted its holdings in shares of Immunome by 840.0% in the 3rd quarter. Sterling Capital Management LLC now owns 3,478 shares of the company’s stock valued at $75,000 after buying an additional 3,108 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Latest Immunome News

These are some of the IMNM news items that stood out recently:

• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to a loss of $0.76 from $0.68, and reduced full-year EPS estimates to losses of $2.64 for 2026, $2.71 for 2027, $2.41 for 2028, $1.63 for 2029, and $0.42 for 2030. The largest revisions include turning its 2029 forecast from a $0.40 profit to a loss, and its 2030 forecast from a $1.08 profit to a loss. These changes signal weaker expected earnings. Immunome analyst estimates
• Negative Sentiment: Piper Sandler cut its price target for Immunome. Piper Sandler price target cut
• Negative Sentiment: Stifel Nicolaus also lowered its expectations for the stock. Stifel Nicolaus lowers expectations

About Immunome

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.